GlassScriptPhysician profile
Ananya Das
NPI 1669457206
$23,275.35
in general payments reported to CMS, 2019-2025
29 companies · $2,876 in 2025
The $2,876 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,912 · 2020: $13K · 2021: $224 · 2022: $914 · 2023: $667 · 2024: $202 · 2025: $2,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,613 · Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,612.50 |
| Food and Beverage | $1,133.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18,271.11 | 2019-2025 | General - Biliary Devices |
| Olympus Medical Systems Corporation | $2,612.50 | 2025 | Evis Exera III Duodenovideoscope, Disposable Hot Biopsy Forceps |
| Abbvie INC. | $362.40 | 2019-2025 | Linzess, Creon, Viberzi |
| Olympus America INC. | $256.80 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.85 | 2019-2024 | Trulance |
| Janssen Biotech, INC. | $187.66 | 2022-2025 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $178.26 | 2019-2023 | |
| Celgene Corporation | $147.59 | 2022-2024 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $117.14 | 2020 | |
| Medtronic, INC. | $108.09 | 2021-2023 | Gi Genius |
| Fujifilm Healthcare Americas Corporation | $83.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.60 | 2019-2023 | Gattex |
| Ardelyx, INC. | $79.47 | 2022-2024 | Ibsrela |
| Shionogi INC | $70.36 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $57.78 | 2022-2024 | Rebyota |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $55.60 | 2023 | Dupixent |
| Alnylam Pharmaceuticals INC. | $50.88 | 2023 | Givlaari |
| Qol Medical, LLC | $45.79 | 2019 | |
| Ironwood Pharmaceuticals, INC | $39.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $38.30 | 2019-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $34.77 | 2021-2024 | |
| Allergan, INC. | $27.77 | 2019 | |
| Pharmacosmos Therapeutics INC. | $24.93 | 2024 | Monoferric |
| Ucb, INC. | $21.66 | 2019 | |
| Genzyme Corporation | $21.55 | 2022 | |
| Lucid Diagnostics INC. | $20.92 | 2022 | |
| Madrigal Pharmaceuticals | $20.75 | 2025 | Rezdiffra |
| Oxford Immunotec USA INC | $17.67 | 2022 | |
| Novo Nordisk INC | $14.94 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananya Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.